Trial reportEuropean heart journal2024
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.
Trial report in European heart journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 5 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Transcatheter versus surgical aortic valve replacement in low-risk patients with severe aortic stenosis: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk: An Individual Participant Data Meta-Analysis.JAMA cardiology · 2025Pooled it
- Incidence of Coronary Obstruction During Aortic Valve Implantation: Meta-Analysis and Mixt-Treatment Comparison of Self-Expandable Versus Balloon-Expandable Valve Prostheses.Reviews in cardiovascular medicine · 2025Pooled it
- Incidence of aortic valve reintervention in patients with aortic stenosis undergoing transcatheter aortic valve implantation versus surgical aortic valve replacement: a systematic review and updated meta-analysis of randomized studies.General thoracic and cardiovascular surgery · 2025Pooled it
- Trends in Transcatheter Versus Surgical Aortic Valve Replacement Outcomes in Patients With Low-Surgical Risk: A Systematic Review and Meta-Analysis of Randomized Trials.Journal of the American Heart Association · 2024Pooled it
- Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial.JAMA cardiology · 2026Trial
- Differential impact of institutional procedural volume on outcomes of transcatheter and surgical strategies for concomitant aortic stenosis and coronary artery disease: a nationwide registry study.Cardiovascular intervention and therapeutics · 2026Article
- Impact of short membranous septal length on overall survival after transcatheter aortic valve replacement.Heart and vessels · 2026Article
- Longitudinal Trends and Outcomes in Transcatheter Aortic Valve Implantation: a report from the SwissTAVI Registry.Cardiovascular intervention and therapeutics · 2026Article
- Midterm outcomes after TAVR or SAVR in low-risk patients with severe aortic stenosis in the real clinical practice in Japan.Cardiovascular intervention and therapeutics · 2026Article
- Seven years of PARTNER 3: the evolution of a lifetime valve strategy, reassurance and residual uncertainty.Journal of thoracic disease · 2026Article
- Surgery that looks like transcatheter aortic valve implantation: the transaxillary concept for minimally invasive aortic valve replacement in 1,848 consecutive patients.Annals of cardiothoracic surgery · 2026Article
- Article
- Ten-Year Clinical Outcomes and Valve Durability After Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves.JACC. Asia · 2026Article
- Transcatheter aortic valve implantation: contemporary management from first valve choice to reintervention.Internal medicine journal · 2026Review
- Durability Analysis of a Self-Expanding Transcatheter Aortic Valve Through 30 Years of Accelerated Wear Testing.Structural heart : the journal of the Heart Team · 2026Article
- Long-term outcomes after aortic valve replacement in low risk and younger patients: what evidence is available and what is still missing?Journal of thoracic disease · 2026Article
- Emergency Transcatheter Aortic Valve Replacement in Cardiogenic Shock Caused by Severe Bicuspid Aortic Valve Stenosis.JACC. Case reports · 2026Article
- Complete versus incomplete coronary revascularisation in patients undergoing PCI after TAVI.Open heart · 2026Observational
- Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management.European journal of clinical investigation · 2026Review
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsTranscatheter aortic valve implantation (TAVI) has become a viable treatment option for patients with severe aortic valve stenosis across a broad range of surgical risk. The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize patients at lower surgical risk to TAVI or surgical aortic valve replacement (SAVR). The aim of the present study was to report clinical and bioprosthesis outcomes after 10 years.
methodsThe NOTION trial randomized 280 patients to TAVI with the self-expanding CoreValve (Medtronic Inc.) bioprosthesis (n = 145) or SAVR with a bioprosthesis (n = 135). The primary composite outcome was the risk of all-cause mortality, stroke, or myocardial infarction. Bioprosthetic valve dysfunction (BVD) was classified as structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis according to Valve Academic Research Consortium-3 criteria. Severe SVD was defined as (i) a transprosthetic gradient of 30 mmHg or more and an increase in transprosthetic gradient of 20 mmHg or more or (ii) severe new intraprosthetic regurgitation. Bioprosthetic valve failure (BVF) was defined as the composite rate of death from a valve-related cause or an unexplained death following the diagnosis of BVD, aortic valve re-intervention, or severe SVD.
resultsBaseline characteristics were similar between TAVI and SAVR: age 79.2 ± 4.9 years and 79.0 ± 4.7 years (P = .7), male 52.6% and 53.8% (P = .8), and Society of Thoracic Surgeons score < 4% of 83.4% and 80.0% (P = .5), respectively. After 10 years, the risk of the composite outcome all-cause mortality, stroke, or myocardial infarction was 65.5% after TAVI and 65.5% after SAVR [hazard ratio (HR) 1.0; 95% confidence interval (CI) 0.7-1.3; P = .9], with no difference for each individual outcome. Severe SVD had occurred in 1.5% and 10.0% (HR 0.2; 95% CI 0.04-0.7; P = .02) after TAVI and SAVR, respectively. The cumulative incidence for severe NSVD was 20.5% and 43.0% (P < .001) and for endocarditis 7.2% and 7.4% (P = 1.0) after TAVI and SAVR, respectively. No patients had clinical valve thrombosis. Bioprosthetic valve failure occurred in 9.7% of TAVI and 13.8% of SAVR patients (HR 0.7; 95% CI 0.4-1.5; P = .4).
conclusionsIn patients with severe AS and lower surgical risk randomized to TAVI or SAVR, the risk of major clinical outcomes was not different 10 years after treatment. The risk of severe bioprosthesis SVD was lower after TAVR compared with SAVR, while the risk of BVF was similar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.